Last reviewed · How we verify
L-arginine (L-arginine Veyron)
L-arginine (L-arginine Veyron) is a Amino acid supplement Small molecule drug developed by University Hospital, Strasbourg, France. It is currently FDA-approved for Vascular dysfunction and endothelial dysfunction, Cardiovascular disease management.
L-arginine is a semi-essential amino acid that serves as a substrate for nitric oxide synthase, increasing nitric oxide production to improve vascular function and blood flow.
L-arginine is a semi-essential amino acid that serves as a substrate for nitric oxide synthase, increasing nitric oxide production to improve vascular function and blood flow. Used for Vascular dysfunction and endothelial dysfunction, Cardiovascular disease management.
At a glance
| Generic name | L-arginine (L-arginine Veyron) |
|---|---|
| Sponsor | University Hospital, Strasbourg, France |
| Drug class | Amino acid supplement |
| Target | Nitric oxide synthase (substrate) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
L-arginine acts as a precursor for nitric oxide (NO) synthesis via the enzyme nitric oxide synthase. Increased NO production leads to vasodilation, improved endothelial function, and enhanced blood flow. This mechanism underlies its use in cardiovascular and vascular disorders where endothelial dysfunction is a contributing factor.
Approved indications
- Vascular dysfunction and endothelial dysfunction
- Cardiovascular disease management
Common side effects
- Gastrointestinal disturbance
- Nausea
- Diarrhea
- Abdominal pain
Key clinical trials
- Protective Effects of L-arginine During Reperfusion by Femoropopliteal Bypass for Lower Limb Ischemic Syndrome in Humans (PHASE4)
- L-Arginine Treatment for Severe Vascular Fetal Intrauterine Growth Restriction: a Randomized Double Bind Controlled Trial (L Arginine in IUGR) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- L-arginine (L-arginine Veyron) CI brief — competitive landscape report
- L-arginine (L-arginine Veyron) updates RSS · CI watch RSS
- University Hospital, Strasbourg, France portfolio CI
Frequently asked questions about L-arginine (L-arginine Veyron)
What is L-arginine (L-arginine Veyron)?
How does L-arginine (L-arginine Veyron) work?
What is L-arginine (L-arginine Veyron) used for?
Who makes L-arginine (L-arginine Veyron)?
What drug class is L-arginine (L-arginine Veyron) in?
What development phase is L-arginine (L-arginine Veyron) in?
What are the side effects of L-arginine (L-arginine Veyron)?
What does L-arginine (L-arginine Veyron) target?
Related
- Drug class: All Amino acid supplement drugs
- Target: All drugs targeting Nitric oxide synthase (substrate)
- Manufacturer: University Hospital, Strasbourg, France — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Vascular dysfunction and endothelial dysfunction
- Indication: Drugs for Cardiovascular disease management
- Compare: L-arginine (L-arginine Veyron) vs similar drugs
- Pricing: L-arginine (L-arginine Veyron) cost, discount & access